Aradigm Corporation Logo

Email this page: News Release

Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by Aradigm Corporation for any marketing purposes.

Send:       


 
This helps Aradigm Corporation prevent automated submissions.